tbuckley/cabot-search huggingface dataset:
Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
Authors: Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej J Jakubowiak, Nizar J Bahlis, Rachid Baz, Gail Larkins, Min Chen, Mohamed Zaki, Kenneth C. Anderson
Journal: Blood (2011)
Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial
Authors: Thorsten Zenz, Peter Dreger, Sascha Dietrich, Sebastian Böttcher, Matthias Ritgen, Dirk Winkler, Andreas Bühler, Donald Bunjes, Dietrich Beelen, Sandra Cohen, Ute Hegenbart, Matthias Zeis, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2010)
Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network.
Authors: T. H. Cartwright, M. Clayton, J. S. Garey, K. A. Boehm
Journal: Journal of Clinical Oncology (2010)

3626 Background: We believe that the use of Level I Pathways (an evidence-based algorithm for patient [pt] treatment), established by US Oncology Network (USON) physicians, in conjunction with an electronic health record (EHR), specifically iKnowMed, has improved the level of pt care. An improvement in care should translate to improvement in outcomes, specifically progression-free survival (PFS). This study was conducted to compare the PFS of colorectal (CR) pts treated at USON sites to the published results of the BEAT and BRITE registry studies. Methods: Over 31,869 CR pt records are stored in USON's iKnowMed database. The data were mined for CR cancer pts receiving first-line treatment from July 1, 2006 to September 30, 2009. We compared PFS to the BEAT ( Berry, et al ASCO 2008) and BRITE (Kozloff, et al ASCO 2008) registry studies. Secondary analysis included stratification by Karnofsky PS and age. Pts were excluded if they had no PFS data entered, data entry errors (calculated PFS was negative), or if PFS = 0. Results: Median PFS for USON pts (n = 2,746) was 11.2 months (compared to BEAT median PFS=10.8 months and BRITE PFS = 10.0 months). By age (< 65 [n = 1,312], 65-74 [n = 746], and ≥ 75 [n = 688]) median PFS was 11.6, 11.4, and 9.8 months, respectively. In BRITE, median PFS for these age groups was 10.2, 9.7, and 9.8 months, respectively. By PS (80-100 [n = 1,808] and ≤ 70 [n = 388]), median PFS for USON pts was 11.4 and 9.3 months, respectively. Conclusions: Based on these findings, PFS for USON CR pts treated with Level I Pathways (using iKnowMed) is as good, if not longer, than published findings of both the BEAT and BRITE registry studies, overall and by age, as well as other published phase III first-line trials. Prior studies with iKnowMed have shown that it results in reduced costs; further, errors are minimized by reducing variability and outcomes (specifically PFS) are improved. This study is a “stepping off” point to explore the potential impact on outcomes achieved by using USON's evidence-based Level I Pathways to direct pt care. Future studies may be done to explore PFS by regimen. No significant financial relationships to disclose.
TMIC-06. IDENTITY AND GENE PROFILE OF TUMOR-ASSOCIATED MACROPHAGES IN GLIOBLASTOMA
Authors: Zhihong Chen, Xi Feng, Kai Nie, Winnie W. Pong, Rikke Rasmussen, David Gutmann, Dolores Hambardzumyan
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most aggressive and common type of brain tumor in adults, with patient survival times of approximately one year following diagnosis. The GBM microenvironment is composed of numerous non-neoplastic cells, including vascular endothelia, various infiltrating and resident immune cells, and non-neoplastic glial cells. The most abundant non-neoplastic cell population in the GBM microenvironment is tumor-associated macrophages (TAMs). TAMs comprise mixed populations of myeloid cells, including infiltrating macrophages from the blood circulation and resident brain microglia. TAMs are recruited to the GBM microenvironment, where they are hypothesized to perform immunosuppressive functions and release growth factors and cytokines in response to factors produced by neoplastic cells. In an effort to delineate the temporal and spatial dynamics of TAM composition during malignant gliomagenesis, we employed genetically-engineered mouse models of PDGF-driven GBM in combination with double-transgenic reporter mice that express GFP (green fluorescent protein) or RFP (red fluorescent protein) under the control of CX3CR1 or CCR2 promoters, respectively. Using this approach, we demonstrated that CX3CR1LoCCR2Hi monocytes are recruited to the GBM, where they transition in situ to CX3CR1HiCCR2Lo macrophages and CX3CR1HiCCR2- microglia-like cells. We found that infiltrating macrophages constitute ~80% of the total TAM population, with resident microglia accounting for the remaining ~20% of TAMs. Bone marrow-derived infiltrating cells (macrophages) preferentially localize to perivascular areas. In contrast, resident microglia are mainly localized to peri-tumoral regions. Additionally, RNA-sequencing analyses revealed differential gene expression patterns unique to infiltrating and resident cells, suggesting unique functions for each TAM population. Collectively, these results demonstrate the unique spatial and temporal differential composition, as well as distinct anatomical localizations for infiltrating and resident monocytes in GBM. Our study provides a strong rationale for targeting infiltrating cells, the major component of TAMs, in future stroma-directed therapeutic approaches against this deadly neoplasm.
Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).
Authors: Johanna A. Kremer Hovinga, Rahel Zahnd, James N. George, Sara K. Vesely, Deirdra R. Terrell, Khatira Abulsatova, Jing-fei Dong, Brenda Luken, Jan J. Voorberg, Bernhard Lammle
Journal: Blood (2006)
EPID-12. DEMOGRAPHICS AND LIFESTYLE FACTORS IN GLIOMA RISK: A REPORT FROM THE GLIOMA INTERNATIONAL CASE-CONTROL STUDY
Authors: E. Susan Amirian, Georgina Armstrong, Renke Zhou, Margaret Wrensch, Sara Olson, Michael Scheurer, Dora Il’yasova, Daniel Lachance, Ching Lau, Elizabeth Claus, Jill Barnholtz-Sloan, Joellen Schildkraut, Francis Ali-Osman, Siegal Sadetzki, Christoffer Johansen, Richard Houlston, Robert Jenkins, Jonine Bernstein, Ryan Merrell, Faith Davis, Rose Lai, Sanjay Shete, Christopher Amos, Beatrice Melin, Melissa Bondy
Journal: Neuro-Oncology (2016)

Although previous studies have examined the role of demographic and lifestyle factors in glioma etiology, there are few established associations between such factors and glioma risk. The incidence of glioma is 2-3 times higher among non-Hispanic whites compared to blacks, Asians, or other racial/ethnic groups, but the reasons behind this remain unclear. As one of the largest glioma study populations available, the Glioma International Case-Control Study (GICC) provides an unprecedented opportunity to explore the associations between glioma risk and a number of lifestyle and demographic factors, stratified by race/ethnicity. The GICC is a 14-site consortium with data on 4533 cases and 4171 controls collected from five countries. Using these data, we examined following exposures of interest: birth order, family history of glioma, birth season, dexterity, “usual adult” BMI, physical activity levels, smoking history, and alcohol consumption. We calculated age- and sex-adjusted meta-analysis ORs (mOR), using two-stage random-effects restricted maximum likelihood modeling. In our case-case comparisons, we found that there was a preponderance of younger cases among racial/ethnic minorities compared to non-Hispanic whites, and this trend persisted even among glioblastoma cases. With regard to family history, a positive family history of glioma increased glioma risk across all races/ethnicities, though not always significantly. By contrast, the association between body mass index (BMI) and glioma risk was not consistent across all racial/ethnic groups. Among African-American cases and controls, being overweight was associated with a significantly increased glioma risk compared to being normal/underweight (pOR: 2.36, 95% CI: 1.09-5.10); yet among the other races/ethnicities, being overweight was not significantly associated with glioma risk. Overall, this study adds new information to the literature on whether potential associations with our factors of interest (i.e., family history, physical activity, BMI) were consistent by race/ethnicity. Although our analyses were exploratory, they contribute new information to the existing epidemiologic literature.
Room for improvement? The adoption of multimodal esophageal cancer care in the United States.
Authors: R. P. Merkow, K. Y. Bilimoria, M. McCarter, A. Stewart, W. B. Chow, R. Williams, C. Y. Ko, D. J. Bentrem
Journal: Journal of Clinical Oncology (2011)

78 Background: Consensus guidelines recommend neoadjuvant chemo- or chemoradiation therapy as the preferred treatment for locally advanced esophageal adenocarcinoma; however, it is unknown if this recommendation has been widely adopted in the U.S. Our objective was to examine esophageal cancer multimodal therapy and identify factors associated with the use of neoadjuvant therapy. Methods: From the National Cancer Data Base, patients with middle third, lower third and GE junction (GEJ) adenocarcinomas were identified. Patients who were clinical stage I-III and underwent surgical resection were included. Separate logistic regression models were developed to identify predictors of neoadjuvant therapy utilization and outcomes. Results: From 1998 to 2007, 8,051 patients underwent surgical resection for esophageal cancer: 16.3% stage I, 45.0% stage II and 38.7% stage III. For stage II/III tumors, neoadjuvant use increased (49.0% to 77.8%, p&lt;0.001). After adjustment, factors associated with underuse of neoadjuvant therapy in stage II/III patients were older age, Black or Hispanic ethnicity, more severe comorbidities, tumor location (GEJ and middle vs. lower third), tumor size ≥ 2cm, stage II (vs. III) and geographic region. Stage II/III patients not receiving neoadjuvant had an over two fold increased risk of positive lymph nodes (OR 2.14. 95% CI 1.79 – 2.55, p&lt;0.001). In addition, the positive surgical margin rate increased almost three fold (OR 2.80 95% CI 2.17-3.62, p&lt;0.001) but 30-day postoperative mortality risk was not significantly affected (OR 1.50 95% CI 0.94-2.39; p=0.090). For stage I patients, neoadjuvant therapy decreased over time (38.0% to 11.4%, p&lt;0.001). The overuse of neoadjuvant therapy was associated with higher tumor grade, larger tumor size, and low surgical case volume (all p&lt;0.05). Conclusions: The adoption of neoadjuvant therapy has increased in the past decade; however, opportunity exists to improve guideline treatment for locally advanced esophageal cancer. Registry-based feedback to individual hospitals, such as benchmark comparison tools, could help institutions provide care in concordance with national guidelines. No significant financial relationships to disclose.
Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations
Authors: G. Viscardi, C.M. Della Corte, F. Papaccio, G. Esposito, M. Fasano, E. Martinelli, T. Troiani, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2016)
Post-That Washing Prior to Transplantation of Umbilical Cord Blood (UCB) That Were Depleted of Plasma but Not of Red Blood Cells.
Authors: Robert Chow, Patrick Tan, Tang-Her Jaing, Joseph Rosenthal, Auayporn Nademanee, Chatchada Karanes, Michael Graham, Gretchen Eames, Lee Lee Chan, Brian Wang, Tiffany Chow, Tina Wu, Ah Moy Tan, Poh-Lin Tan, Hai-Peng Lin, David Gjertson, Lawrence Petz
Journal: Blood (2006)
Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)
Authors: Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, Barbara Di Camillo, Milena Lodola, Francesca Ricci, Mauro Turrini, Marzia Varettoni, Sara Rattotti, Enrica Morra
Journal: Blood (2012)
IMST-08. EXPRESSION OF PDL-1 ON PITUITARY ADENOMAS: A ROLE FOR IMMUNOTHERAPY
Authors: Aladine A. Elsamadicy, S. Harrison Farber, Pakawat Chongsathidkiet, Karolina Woroniecka, Xiuyu Cui, Peter Fecci
Journal: Neuro-Oncology (2016)

Cushing’s disease (CD) is caused by an ACTH-secreting pituitary adenoma that stimulates the production and release of cortisol by the adrenal glands. It affects millions of people annually, causing hypertension, obesity, osteoporosis, cognitive dysfunction and even early death. First-line treatment for CD is surgical adenomectomy, but 25% of these patients will recur within 5 years, many failing subsequent therapies. Novel treatments, such as immunotherapy, are wanted, but remain untested. Our finding here of PDL-1 expression on pituitary adenomas provides a promising immunotherapeutic target. For human studies, immunohistochemistry (IHC) was used to determine the expression of PDL-1 in 19 human pituitary adenoma samples, including 9 ACTH-secreting adenomas. For murine in vitro studies, the ACTH-secreting pituitary adenoma ATT20/D16v cell line was assayed by flow cytometry and RT-qPCR. For in vivo studies, ATT20/D16v cells were implanted into the flank of A/HeJ x C57L/J F1 mice. Tumor volume and mouse weight were assessed over time. PDL-1 levels were assessed by the same methods on harvested tumors as well as from control mouse pituitary glands. Our data reveal the upregulated expression of PDL-1 on pituitary adenomas of both patients and mice compared to normal pituitary. Human pituitary adenomas demonstrate significant (i.e. ≥1% staining) PDL-1 expression in 32% of samples, including 22% of ACTH-secreting adenomas. Similar findings are observed in mice, where the ATT20/D16v cell line, as well as tumor grown subcutaneously in flank both demonstrate elevated PDL-1 expression,. Furthermore, mice implanted with such tumors develop clinical signs of Cushing’s disease. PDL-1 is found significantly elevated on ACTH-secreting pituitary adenomas in patients and mice and are anticipated to represent a viable immunotherapeutic target. A newly established model of murine Cushing’s disease will permit pre-clinical evaluation of anti-PDL-1 monoclonal antibodies.
Graft-Failure After Allogeneic Stem Cell Transplantation. Outcome and Prognostic Factors in 80 Patients
Authors: Christelle Ferrà, Jaime Sanz, Miguel-Angel Díaz-Pérez, Mireia Morgades, Jorge Gayoso, José-Rafael Cabrera, María-Teresa Villaescusa, Guillermo Sanz, Francesc Fernández-Avilés, Carlos Solano, Rafael F. Duarte, Miguel Ortin, Inmaculada Heras, Moraleda José-María, Javier De la Serna, Barrenetxea Cristina, Josep-Maria Ribera
Journal: Blood (2011)
Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience
Authors: E.S. Lutrino, L. Orlando, G. Giordano, C. Zamagni, C. Caliolo, A. Febbraro, M. Giampaglia, G. Dima, A. Quaranta, C. Scavelli, D. Bilancia, G. Filippelli, C. Fontanella, P. Schiavone, P. Fedele, M. Enrica, D. Rubino, S. Cinieri
Journal: Annals of Oncology (2016)
Effect of a novel FAK inhibitor targeted to the binding site of VEGFR3 on pancreatic cancer proliferation in vitro and in vivo.
Authors: E. V. Kurenova, J. Liao, D. He, D. L. Hunt, A. Chekhau, S. N. Hochwald, D. A. Ostrov, W. G. Cance
Journal: Journal of Clinical Oncology (2011)

214 Background: Even with successful surgical resection and treatment pancreatic adenocarcinoma has a high incidence of recurrence because of metastatic spread. Vascular endothelial growth factor receptor 3 (VEGFR3) is related to lymphatic metastasis. VEGFR3 binds to the survival protein, focal adhesion kinase (FAK), to promote pancreatic cancer (PC) lymphangiogenesis. In this study we have pinpointed the site of interaction of VEGFR3 and FAK to create drug capable of disrupting their signaling with antitumor effect. Methods: 200,000 small molecules were screened in silico for their abilities to interact with the VEGFR3 /FAK binding site. Effects of the selected compounds on PC cell lines MiaPaCa2 and Panc1 were examined by MTT assay (viability), BrdU incorporation (proliferation), Boyden chamber (motility), TUNEL and flow cytometry (cell cycle, apoptosis), and Western blot (phosphorylation, apoptosis). Results: We selected compound C4 because it disrupted the FAK-VEGFR3 complexes in PC cells, as was shown by immunoprecipitation. It caused a dose-dependent dephosphorylation and inactivation of the VEGFR3. Inhibition of VEGFR3 with 10μM of C4 resulted in 80% reduction in cell viability, decrease in proliferation and a 50% reduction in motility. Treatment led to apoptosis in PC cells, confirmed by PARP cleavage. C4 increased the sensitivity of PC cells to chemotherapy in vitro. MiaPaca2 have shown 40% apoptosis after only 24 h of treatment with combination of C4 and gemcitabine at nanomolar concentrations ineffective alone. C4 reduced tumor growth in vivo in murine models of PC. C4 (60 mg/kg, daily IP) decreased tumor growth after 21 days of treatment to 60% (P=0.017). Lower dose of the C4 (10 mg/kg) still had an effect and inhibited tumor growth by 30%, but concomitant administration with low dose of gemcitabine (4 mg/kg, Q4dx6), had significant synergistic effect and led to 80% of tumor reduction. We also have shown that combination of C4 with gemcitabine had prolonged cytostatic effect on tumor growth after treatment withdrawal. Conclusions: Targeting the scaffolding function of FAK with the small-molecule inhibitors can be effectively used to develop potential oral-based PC therapeutics. [Table: see text]
Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.
Authors: Yu-Tzu Tai, Kihyun Kim, Xian-Feng Li, Mariateresa Fulciniti, Weihua Song, Sabikun Nahar, Peter Burger, Mathew J. Rumizen, Klaus Podar, Dharminder Chauhan, Teru Hideshima, Robert L Schlossman, Nikhil C. Munshi, Paul Richardson, Ann Clark, Janet Ogden, Goutopoulos Andreas, Luca Rastelli, Kenneth C. Anderson
Journal: Blood (2009)
Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors
Authors: I. Labidi-Galy, K.M. Elias, P. Tsantoulis, A. Vitonis, L. Doyle, J. Hornick, D.W. Cramer, M. Goggins, C.L. Kerr, M. Birrer, M. Hirsch, R. Drapkin
Journal: Annals of Oncology (2016)
Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: phase Ib KEYNOTE 200 study
Authors: H.S. Pandha, K. Harrington, C. Ralph, A. Melcher, E. Schmidt, D.R. Kaufman, M. Grose, R. Karpathy, D. Shafren
Journal: Annals of Oncology (2016)
Malnutrition in 822 Irish cancer patients undergoing chemotherapy: prevalence and impact on quality of life and survival
Authors: L.E. Daly, É Ní Bhuachalla, S. Cushen, D. Power, S. O'Reilly, P. McEneaney, D. O'Mahony, R. Bambury, A. Ryan
Journal: Annals of Oncology (2016)
Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia
Authors: Chau-To Kwok, Amy D. Marshall, John E. J. Rasko, Justin J. L. Wong
Journal: Journal of Hematology & Oncology (2017)

The online version of the original article can be found under doi: 10.1186/s13045-017-0410-6  .
A real-world study of patterns of Bacillus Calmette-Guerin (BCG) use and associated adverse events (AEs) in non-muscle invasive bladder cancer (NMIBC) patients in the United States
Authors: K. Wilson, E. Malangone-Monaco, S. Satram-Hoang, D. Diakun, S.-W. Lin, D. Tayama, S. Ogale
Journal: Annals of Oncology (2016)
First-line (1-L) bevacizumab plus chemotherapy (Bev/CT) in colorectal cancer (CRC) patients with potentially resectable liver only (LM) or liver and lung metastases (LLM): KRAS mutation analysis of the non-interventional PICASSO study
Authors: D. Malka, J.-P. Metges, D. Elias, J. Bennouna, F. Bonnetain, L.-M. Dourthe, M. Ben Abdelghani, A. Radji, P. Laplaige, F. Petit Laurent, J. Telliez, S. Bakiri, M. Rivoire
Journal: Annals of Oncology (2016)
ANTI-Leukemic Activity of DNA Methyltransferase Inhibitors Azacitidine and Decitabine On AML1-ETO Positive CELLS Is Evident At LOW Doses and Selectively Mediated by Epigenetic Mechanisms
Authors: Francesca Buchi, Elena Spinelli, Erico Masala, Ana Valencia, Alessandro Sanna, Antonella Gozzini, Valeria Santini
Journal: Blood (2012)
Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience
Authors: Lionel Ades, Mathilde Lamarque, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, Francois Dreyfus, Odile Beyne Rauzy, Pascal Turlure, Norbert Vey, Christian Recher, Caroline Dartigeas, Laurence Legros, Jacques Delaunay, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux
Journal: Blood (2012)
Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies.
Authors: Tetsuzo Tauchi, Daigo Akahane, Kousuke Nunoda, Seiichi Okabe, John Pollard, Kazuma Ohyashiki
Journal: Blood (2007)
Saving in clinical trial: a possible challenge for health care
Authors: C. Taverniti, M. Pradotto, L. Rossi, G. Ignazzi, E. Cibrario Rocchietti, D. Battista, D. Polizzano, A. Linardi, M. Gianetta, A. Alemanni, P. Demartini, F. Arizio, A. Nuzzo, C. Cagnazzo, C. Bonfadini
Journal: Annals of Oncology (2016)